GET DAILY SIGNALSProQR Therapeutics (PRQR): Examining Its RNA Editing Platform and Lilly Collaboration
Key Takeaways
- PRQR is the Nasdaq ticker for ProQR Therapeutics N.V., a clinical-stage biotechnology company headquartered in Leiden, the Netherlands.
- The company develops RNA-based medicines, anchored by its proprietary Axiomer RNA editing platform for genetic disorders with unmet medical needs.
- Its lead candidate, AX-0810, targets cholestatic liver diseases and is currently in early clinical development.
- ProQR has a long-standing research and licensing collaboration with Eli Lilly to advance RNA-editing therapies.
- As a pre-revenue, clinical-stage biotech, the company faces typical risks tied to clinical trials, regulatory approval, and capital needs.
Introduction
ProQR Therapeutics N.V. (PRQR) focuses on discovering and developing novel RNA-based medicines for severe genetic diseases. What draws my attention is its Axiomer RNA editing technology platform, which aims to correct or modulate gene expression at the RNA level instead of making permanent changes to DNA. As a clinical-stage firm with no approved products yet, its finances reflect ongoing research costs offset by collaboration revenue rather than sales.
Company Background and Operations
ProQR Therapeutics was established in 2012 by Daniel de Boer, Gerard Platenburg, the late Henri Termeer, and Dinko Valerio. Incorporated under Dutch law, it maintains its headquarters in Leiden, the Netherlands, at Zernikedreef 9. Shares have traded on Nasdaq since September 2014 under the symbol PRQR on the Nasdaq Capital Market.
The company reports a single segment centered on RNA-based therapeutics discovery and development. Its Axiomer platform employs short engineered oligonucleotides to engage natural ADAR enzymes for precise edits in mRNA. These changes can address mutations, adjust protein levels, or add protective modifications. Acting on RNA rather than DNA, the effects are intended to be temporary and reversible, which the firm highlights as a potential safety edge compared to permanent gene-editing methods.
Pipeline Focus and Revenue Streams
The lead Axiomer program, AX-0810, targets NTCP to address cholestatic diseases involving toxic bile acid buildup in the liver. Additional efforts target Rett syndrome, metabolic dysfunction-associated steatohepatitis (MASH), and cardiovascular disease. Earlier work included RNA therapies for rare retinal conditions such as Leber congenital amaurosis type 10.
Without commercial products, revenue comes mainly from partnerships. The key arrangement is a global research and licensing deal with LLY (Eli Lilly and Company), initiated in 2021 and expanded since. It applies the Axiomer platform to liver and nervous system targets, providing ProQR with upfront payments, milestones, and potential royalties.
Why PRQR Draws Investor Interest
Interest in PRQR stems from the longer-term promise of RNA editing as a therapeutic approach. Unlike some RNA-interference methods focused mainly on reducing expression, Axiomer seeks to correct or adjust specific targets, which could expand its applicability. The Eli Lilly partnership adds validation and non-dilutive funding potential, while the emphasis on rare and underserved conditions points to meaningful unmet need if trials succeed.
ProQR competes as an emerging platform biotech against established RNA firms and newer gene-editing players. Its edge lies in the precision and reversibility of the RNA-editing method, plus flexibility across therapeutic areas. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Risks and Key Considerations
Clinical-stage biotechs like ProQR carry significant risks. Candidates must prove safety and efficacy through trials and gain regulatory approval amid high failure rates. The firm has posted operating losses and depends on collaboration income, equity raises, and other financing. Other factors include competition in the evolving RNA and genetic medicine space, reliance on the Eli Lilly tie-up, and the challenge of moving preclinical data into approved treatments. As a Dutch company reporting under IFRS, its financials may also differ from U.S. peers.
Wrapping Up
ProQR Therapeutics stands out as a clinical-stage biotech with its Axiomer RNA editing platform and emphasis on genetic diseases lacking good options. Its position rests on a differentiated scientific method and the prominent Eli Lilly collaboration, though it remains exposed to the usual uncertainties of early drug development. In my view, PRQR offers a speculative, innovation-oriented profile in genetic medicine rather than a commercial revenue business.
Using Tickeron Tools for Biotech Research
When analyzing names like PRQR, I often turn to Tickeron’s AI Screener as part of my process. It is an AI-powered platform that helps identify opportunities through technical indicators, fundamentals, volatility, trends, AI signals, industries, patterns, and custom filters. This allows efficient screening of thousands of stocks and ETFs to match specific strategies, whether focused on biotechnology or other sectors.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PRQR saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for PRQR moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 59 similar instances where the indicator exited the overbought zone. In 50 of the 59 cases the stock moved lower. This puts the odds of a downward move at 85%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 50-day moving average for PRQR moved below the 200-day moving average on November 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRQR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for PRQR entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PRQR's RSI Indicator exited the oversold zone, 24 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on PRQR as a result. In 80 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for PRQR just turned positive on October 28, 2026. Looking at past instances where PRQR's MACD turned positive, the stock continued to rise in 35 of 44 cases over the following month. The odds of a continued upward trend are 80%.
Following a +6.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRQR advanced for three days, in 173 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
PRQR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.397) is normal, around the industry mean (3.498). P/E Ratio (-3.375) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (9.294) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. PRQR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRQR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company with interest in the discovery and development of therapeutics for the treatment of genetic disorders
Industry Biotechnology
Advertisement